Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is BPC-157?
BPC-157 (Body Protective Compound 157) is a synthetic 15-amino acid peptide derived from a partial sequence of a body protection compound found naturally in human gastric juice. It was first described in research from the laboratory of Stjepan Sikiric at the University of Zagreb, where it has been studied for several decades in animal models.
The peptide sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is stable in gastric acid, which is unusual for peptides and is central to the oral administration argument — most peptides are degraded in the GI tract before reaching systemic circulation.
BPC-157 is not derived from exogenous sources such as animals or plants. It is a fragment of a larger endogenous human protein, which proponents argue gives it a favorable safety precedent compared to purely synthetic novel molecules.
Mechanism of Action
BPC-157 operates through multiple intersecting pathways, which explains its broad effects across different tissue types in animal models:
- Angiogenesis stimulation: Promotes formation of new blood vessels via VEGF upregulation. This is central to its wound-healing and tissue repair effects.
- Growth hormone receptor sensitization: Enhances tissue sensitivity to growth hormone without raising circulating GH levels — a downstream amplification effect.
- Nitric oxide modulation: Influences nitric oxide synthase (both eNOS and nNOS), affecting blood vessel tone and gut motility.
- VEGF upregulation: Vascular endothelial growth factor stimulation accelerates healing in damaged tissue by increasing vascular supply to the repair site.
- Tendon fibroblast activation: Directly stimulates tendon-to-bone healing via Egr-1 transcription factor pathway and collagen synthesis.
- GABAergic modulation: Some evidence for CNS effects via dopamine and GABA receptor interactions, which may underlie reported neuroprotective effects.
Gut Healing Evidence
The GI evidence base for BPC-157 is the most developed area, though it remains overwhelmingly animal-based:
- Peptic ulcer models: Consistent acceleration of gastric and duodenal ulcer healing in rat models across multiple independent research groups. BPC-157 outperforms omeprazole in some models on mucosal healing speed.
- IBD/colitis models: Reduces inflammation and promotes mucosal healing in TNBS-induced colitis and other bowel inflammation models in rodents.
- Leaky gut models: Reduces intestinal permeability increases caused by NSAIDs, alcohol, and indomethacin in animal studies.
- Human evidence: Only one small retrospective human case series exists. This is a critical distinction — compelling preclinical data does not automatically translate to human efficacy. Multiple longevity medicine physicians who review this space acknowledge the animal evidence is among the best for any peptide, but caution that clinical translation requires human trials that have not yet been conducted.
Tendon and Muscle Repair
BPC-157 has strong animal evidence for musculoskeletal repair beyond its gut effects:
- Accelerates tendon-to-bone healing via Egr-1 and VEGFR2 pathways in Achilles tendon transection models
- Stimulates collagen synthesis and organization in healing tendons
- Reduces scar tissue formation in muscle crush injuries
- Protects against NSAID-induced gastric damage while facilitating healing — relevant to injury contexts where NSAIDs are commonly used
- Promotes faster recovery in ligament injury models
Athletic communities have adopted BPC-157 widely based on these animal data, with many reporting accelerated recovery from tendon and ligament injuries. This is anecdotal but consistent enough across user populations to be notable, even without clinical trial support.
Systemic Effects
Beyond gut and musculoskeletal applications, BPC-157 shows activity across several organ systems in animal research:
- CNS protection: Reduces dopamine system damage in neurotoxicity models; may protect against traumatic brain injury sequelae
- Anti-inflammatory: Broadly reduces inflammatory markers including TNF-α and IL-6 in multiple models
- Liver protection: Accelerates liver healing after various toxic insults in animal models, including alcohol and drug-induced hepatotoxicity
- Cardiac protection: Some evidence for cardiac protection in ischemia models
Oral vs Injectable Forms
One of the more nuanced decisions with BPC-157 is the route of administration:
Oral (arginine salt form): BPC-157 arginine salt was specifically developed for oral use. The argument is that for gastrointestinal conditions specifically — gut inflammation, leaky gut, IBD — local action in the GI tract may be sufficient and more targeted. The arginine salt form improves stability in acidic gastric environment. Bioavailability to systemic circulation is debated and likely low.
Injectable (subcutaneous or intramuscular): For systemic effects including tendon repair, CNS effects, and systemic anti-inflammation, parenteral routes bypass GI breakdown and deliver the peptide systemically. Subcutaneous injection near the injury site is a common protocol used in athletic recovery contexts, though this practice is based on animal study methodology rather than human trial data.
The most honest assessment: BPC-157 has unusually consistent and mechanistically coherent animal evidence across multiple independent research groups. However, the translation from rodent GI models to human outcomes is not validated. Compelling preclinical data has failed to translate to human trials many times in pharmacology history. This does not make BPC-157 unlikely to work — it means we genuinely do not know.
BPC-157 Forms Comparison
| Form | Best For | Evidence Strength | Bioavailability | Practical Considerations |
|---|---|---|---|---|
| Oral capsule (arginine salt) | GI-specific effects: gut healing, IBD, leaky gut | Animal models — GI focus | Low systemic; high local GI | Easier to administer, no injection skill needed |
| Oral capsule (standard BPC-157) | General use; lower cost | Animal models | Likely degraded in stomach without arginine salt modification | May have reduced efficacy vs arginine salt form |
| Subcutaneous injection | Systemic effects: tendon repair, CNS, anti-inflammation | Animal models — systemic | High (bypasses GI) | Requires reconstitution, sterile technique, refrigeration |
| Intramuscular injection | Local muscle/tendon applications (near injury site) | Animal models | High local concentration | More skill required; not validated in humans |
India Legality and Sourcing
BPC-157 is not listed as a scheduled or controlled substance under India's Drugs and Cosmetics Act or the NDPS Act. It has not been approved as a medicine in India, meaning it cannot be legally marketed or sold as a therapeutic. However, its possession and sourcing occupy an unregulated gray area — the same gray area as many research chemicals in India.
It is sold as a "research chemical" by domestic and international suppliers, primarily in lyophilized powder form requiring reconstitution with bacteriostatic water. Quality verification is a significant concern: without pharmaceutical-grade manufacturing, purity and actual peptide content can vary substantially between suppliers. Third-party HPLC testing certificates are the minimum bar for quality assurance.
Dosing Protocols (Circulating Online)
Important: These are protocols circulated in athletic and longevity communities — they are not validated human dosing protocols and should not be interpreted as recommendations.
- Oral: 250-500mcg daily with arginine salt form, taken on empty stomach
- Subcutaneous injection: 200-500mcg daily or twice daily
- Typical cycle length: 4-12 weeks followed by an off period
- Injury-specific injection: Some protocols suggest injecting near the injury site, based on animal study methodology
What to Monitor
If a physician is supervising use, monitoring may include:
- Liver function tests (ALT, AST) — baseline and at 6-8 weeks
- CRP/hs-CRP — to assess inflammation trajectory
- Subjective GI symptom tracking if used for gut conditions
- Any changes in blood pressure (BPC-157 modulates nitric oxide)
Frequently Asked Questions
In animal models, yes — consistently and convincingly across multiple research groups. In humans, the evidence is limited to anecdotal reports and one small retrospective case series. The animal data is among the most compelling for any research peptide, but clinical translation is unvalidated. Most longevity medicine physicians find the preclinical data credible but appropriately caution that human trials are needed before firm conclusions.
For gut-specific applications, oral arginine salt form may be optimal — delivering the peptide directly to GI tissue where it acts locally. For systemic effects like tendon repair, joint healing, or CNS protection, subcutaneous injection is preferred since oral bioavailability to systemic circulation is low. Many users take oral for maintenance and inject during injury recovery.
BPC-157 is not a scheduled substance in India and is not approved as a medicine. It exists in an unregulated gray area — not illegal to possess, but not legal to sell as a therapeutic. It is sold as a research chemical. The regulatory landscape could change, and users should stay current on any regulatory updates.
No formal human safety studies exist. Animal research shows a favorable safety profile with no reported serious adverse events at therapeutic doses. User-reported effects include mild injection site irritation, occasional nausea (especially with higher oral doses), and lightheadedness. The long-term safety profile in humans is genuinely unknown.
BPC stands for Body Protective Compound. The 157 refers to its identification number in the original research series. It is a 15-amino acid partial sequence of a larger body protection compound found naturally in human gastric juice.